Commission Aversion

Commission aversion is when people avoid taking actions because they fear making a harmful mistake. They prefer doing nothing even if acting would help.

Commission aversion denotes a decision bias where agents disproportionately weight the costs of wrongful action relative to omission, skewing choices toward inaction. This bias manifests in evidentiary weighting and asymmetric loss evaluation within decision-making architectures.

A parent notices their child has a mild but persistent fever. Afraid that giving the wrong medication could make things worse, they repeatedly choose to do nothing—even as the fever climbs and doing nothing causes more harm than a simple dose of children's medicine would have.

In a clinical trial safety monitoring setting, a Data Safety Monitoring Board (DSMB) faces accumulating evidence of modest but consistent drug efficacy with a low adverse-event rate. Commission aversion manifests as asymmetric evidentiary weighting: action-linked risks (drug-induced adverse events, regulatory liability) are assigned disproportionate salience relative to omission costs (continued patient suffering under placebo, delayed access to benefit). The decision threshold for stopping the trial early for benefit is effectively raised beyond what symmetric expected-utility calculation would justify, resulting in suboptimal persistence of the control-arm status quo. A calibrated loss-function audit—explicitly mapping omission-pathway harm distributions against action-pathway distributions—reveals the asymmetric hypothesis weighting and allows threshold adjustment toward normative expected-value alignment.

People imagine bad outcomes from acting and focus on those outcomes. That fear makes them choose inaction more often.

In this system, evidentiary_weighting units increase the salience of action-linked negative outcomes while constraints downweight omission costs, creating a weighting asymmetry across decision nodes. Structural thresholds and loss-sensitive gating bias the policy toward default non-action.

Point out clear benefits of acting and show small risks are unlikely. Give examples where doing something helped.

Reframe the decision by quantifying omission costs and calibrating loss weights to reflect true expected values. Implement decision aids that normalize occasional action and adjust threshold gating to reduce asymmetry.

Missed beneficial interventions; Suboptimal status quo persistence; Avoidable harm from nonresponse

An adversarial actor can weaponize commission aversion by framing corrective actions as high-risk or potentially harmful, creating institutional paralysis. For example, flooding a regulatory body with contested evidence about intervention side-effects can suppress enforcement action. In litigation or policy contexts, opponents can strategically raise speculative harms of acting to exploit the asymmetric loss-weighting architecture. Propagandists can manufacture moral narratives where acting equates to culpability while omission is cast as passive innocence, reinforcing the bias at scale and locking decision-makers into inertial non-intervention.

Decision-makers can build resistance by explicitly quantifying omission costs alongside commission costs in structured decision aids to force symmetric loss accounting. Implementing pre-mortem exercises that surface missed-intervention failures—not just action-caused harms—recalibrates threshold gating toward expected-value reasoning. Institutional protocols requiring documented justification for inaction equivalent to those required for action reduce the structural asymmetry. Regular audits of loss-function assignments across action and inaction pathways expose weighting distortions and enable retroactive threshold calibration.